How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,178 results for

Multiple Endocrine Neoplasia Type 1

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Type 2 gastric neuroendocrine tumor: report of one case Full Text available with Trip Pro

level was significantly increased (3,527 pg/mL) at presentation. A second gastroscopy showed polypoid uplifts in gastric body. Puncture biopsy confirmed the presence of a G2 NET in gastric body. The patient previously had received a pituitary tumor surgery and thyroid gland resection. The diagnosis was multiple endocrine neoplasia type 1 (MEN-1). The treatments included sutent, lanreotide, and traditional Chinese herbs. In this article we described the diagnosis and treatment of a patient with MEN-1 (...) Type 2 gastric neuroendocrine tumor: report of one case In this article we reported a female patient with type 2 gastric neuroendocrine tumor (NET). The patient developed upper abdominal pain, acid reflux, heartburn, nausea, and vomiting without obvious cause 16 years ago. Later, a tumor was found in her stomach. Two years ago, a solid mass was found at the pancreatic head. Somatostatin receptor scintigraphy showed positive result. Puncture biopsy showed the presence of a NET. The serum gastrin

2016 Translational gastroenterology and hepatology

262. Multiple Endocrine Neoplasia, Type 2 (Diagnosis)

Adhering to a surveillance program lessens disease complications. Order genetic counseling for the patient so that gene testing and reproductive options can be discussed. For patient education information, see . Previous References [Guideline] Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid . 2015 Jun. 25 (6):567-610. . . [Guideline] American Society of Clinical Oncology. Multiple Endocrine Neoplasia Type 2 (...) processing > Multiple Endocrine Neoplasia Type 2 (MEN2) Updated: May 31, 2018 Author: Melanie L Richards, MD, MPHE; Chief Editor: George T Griffing, MD Share Email Print Feedback Close Sections Sections Multiple Endocrine Neoplasia Type 2 (MEN2) Overview Practice Essentials Multiple endocrine neoplasias type 2 (MEN2) is an inherited disorder characterized by the development of (MTC), parathyroid tumors, and . MEN2 results from germline mutations in the RET proto-oncogene and is transmitted

2014 eMedicine.com

263. Multiple Endocrine Neoplasia, Type 2 (Follow-up)

Multiple Endocrine Neoplasia, Type 2 (Follow-up) Multiple Endocrine Neoplasia Type 2 (MEN2) Treatment & Management: Approach Considerations, Medullary Thyroid Carcinoma Surgery, Parathyroid Disease Surgery Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) Society of Clinical Oncology. Multiple Endocrine Neoplasia Type 2. Cancer.net. Available at . November 2015; Accessed: May 26, 2018. Raue F, Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) . 2009 Jan-Mar. 8(1):23-8. . . Moley JF, Skinner M, Gillanders WE, Lairmore TC, Rowland KJ, Traugott AL, et al. Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine

2014 eMedicine.com

264. Multiple Endocrine Neoplasia, Type 2 (Overview)

Adhering to a surveillance program lessens disease complications. Order genetic counseling for the patient so that gene testing and reproductive options can be discussed. For patient education information, see . Previous References [Guideline] Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid . 2015 Jun. 25 (6):567-610. . . [Guideline] American Society of Clinical Oncology. Multiple Endocrine Neoplasia Type 2 (...) processing > Multiple Endocrine Neoplasia Type 2 (MEN2) Updated: May 31, 2018 Author: Melanie L Richards, MD, MPHE; Chief Editor: George T Griffing, MD Share Email Print Feedback Close Sections Sections Multiple Endocrine Neoplasia Type 2 (MEN2) Overview Practice Essentials Multiple endocrine neoplasias type 2 (MEN2) is an inherited disorder characterized by the development of (MTC), parathyroid tumors, and . MEN2 results from germline mutations in the RET proto-oncogene and is transmitted

2014 eMedicine.com

265. Multiple Endocrine Neoplasia, Type 2 (Treatment)

Multiple Endocrine Neoplasia, Type 2 (Treatment) Multiple Endocrine Neoplasia Type 2 (MEN2) Treatment & Management: Approach Considerations, Medullary Thyroid Carcinoma Surgery, Parathyroid Disease Surgery Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) Society of Clinical Oncology. Multiple Endocrine Neoplasia Type 2. Cancer.net. Available at . November 2015; Accessed: May 26, 2018. Raue F, Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) . 2009 Jan-Mar. 8(1):23-8. . . Moley JF, Skinner M, Gillanders WE, Lairmore TC, Rowland KJ, Traugott AL, et al. Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine

2014 eMedicine.com

266. PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells Full Text available with Trip Pro

PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells The non-receptor tyrosine kinase, PTK6/BRK, is highly expressed in multiple tumor types, including prostate, ovarian, and breast cancers, and regulates oncogenic phenotypes such as proliferation, migration, and survival. PTK6 inhibition also overcomes targeted therapy resistance of HER2+ breast cancer. Although PTK6 is highly expressed in ER+ Luminal breast cancers, the role of PTK6 in this subtype has (...) not been elucidated. In this study, we investigated the functions of PTK6 in ER+ Luminal breast cancer cells, including those that are relatively resistant to estrogen deprivation or targeted endocrine therapies used in the treatment of ER+ cancers. Enhanced expression of PTK6 in ER+ breast cancer cells enhances growth of ER+ breast cancer cells, including tamoxifen-treated cells. Downregulation of PTK6 in ER+ breast cancer cells, including those resistant to tamoxifen, fulvestrant, and estrogen

2017 NPJ breast cancer

267. Adjuvant Endocrine Therapy for Women With Hormone Receptor Positive Breast Cancer Update on Ovarian Suppression

chemotherapy should receive endocrine therapy but not receive ovarian suppression. 1.5 Women with node-negative cancers 1 cm or less (T1a, T1b) should receive endocrine therapy but not receive ovarian suppression. [Benefits: increasing disease-free survival (DFS), freedom from breast cancer, and freedom from distance recurrence. Harms: worse menopausal symptoms and sexual functioning, including hot flashes, sweating, weight gain, vaginal dryness, and decreased libido.] Evidence quality: Intermediate (...) but not receive ovarian suppression. Recommendation type: Evidence-based; harms outweigh benefits; Evidence quality: High; Strength of Recommendation: Strong Recommendation 1.5 Women with node-negative cancers 1 cm or less (T1a, T1b) should receive endocrine therapy but not receive ovarian suppression. Recommendation type: Evidence-based; harms outweigh benefits; Evidence quality: High; Strength of Recommendation: Strong Qualifying statements: The standard duration of ovarian suppression in the included

2016 American Society of Clinical Oncology Guidelines

268. To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors

Enhancing Specific T cell Therapy)in the multi-line treatment failed advanced solid tumors except non small cell lung cancer,including liver cancer,gastric cancer,esophageal cancer,bone and soft tissue tumors,breast cancer, bladder carcinoma,prostate carcinoma,thyroid cancer, ovarian cancer and so on. The patients must meet the two criteria: human leukocyte antigens (HLA)-A*0201+ and NY-ESO-1 positive cells≥25% by immunohistochemistry. Condition or disease Intervention/treatment Phase Liver Cancer Stage (...) of cancer-testis antigen, is commonly expressed in 10-50% of melanoma, lung, liver, esophageal, breast, prostate, bladder, thyroid and ovarian cancer cases, 60% of multiple myeloma cases, and 70-80% of synovial sarcoma. The NY-ESO-1 TCR cell therapy for synovial sarcoma and melanoma has benefited many patients, but its effect on other solid tumors is still unknown. So we plan to explore its efficacy in many types of solid tumors. The trial is to investigate the safety and tolerability of TAEST16001 cell

2017 Clinical Trials

269. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) Full Text available with Trip Pro

conditions, actual versus perceived benefit of treatments, patient's compliance as well as financial/reimbursement issues, and long-term tolerability of therapy.A meeting of global oncology experts was convened in January 2017 with the belief that there is a gap in clinical practice guidance on several fundamental issues in breast cancer care, particularly in the community setting, where oncologists may encounter multiple tumor types. The goal was to discuss some of the most important questions (...) Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) Management of breast cancer is a rapidly evolving field, and, although evidence-based guidelines are available for clinicians to provide direction on critical issues in patient care, clinicians often left to address these issues in the context of community practice situations with their patients. These include the patient's comorbid

2018 Breast cancer research and treatment

270. Endocrine therapy versus endocrine therapy plus targeted agents as first line treatment in elderly metastatic breast cancer patients: a systematic review and meta-analysis

Endocrine therapy versus endocrine therapy plus targeted agents as first line treatment in elderly metastatic breast cancer patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) : Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review

2019 PROSPERO

271. Second-line endocrine treatment in hormone receptor-positive, endocrine-resistant advanced breast cancer: a systemic review and network meta-analyses

Second-line endocrine treatment in hormone receptor-positive, endocrine-resistant advanced breast cancer: a systemic review and network meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination

2019 PROSPERO

272. Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

and are currently receiving insulin treatment. This study will determine whether REMD-477 can decrease daily insulin requirements and improve glycemic control after 12 weeks of treatment in subjects diagnosed with Type 1 diabetes with fasting C-peptide < 0.2 ng/mL at Screening. The study will be conducted at multiple sites in the United States. Approximately 150 subjects with type 1 diabetes on stable doses of insulin will be randomized in a 1:1:1 fashion into one of three treatment groups. Condition or disease (...) to abstain from smoking during admission periods; Known sensitivity to mammalian-derived drug preparations, recombinant protein-based drugs or to humanized or human antibodies; History of illicit drug use or alcohol abuse within the last 6 months or a positive drug urine test result at screening; History of pancreatitis, pancreatic neuroendocrine tumors or multiple endocrine neoplasia (MEN) or family history of MEN; History of pheochromocytoma, or family history of familial pheochromocytoma; Known

2017 Clinical Trials

273. Treatment of Secondary Hypertension Due to Endocrine Causes

. Genetic testing should be considered for individuals <50 years of age and for all patients with multiple lesions, malignant lesions, bilateral pheochromocytomas or paragangliomas, or a family history of pheochromocytoma or paraganglioma. ©2015 . All rights reserved. Unauthorized use prohibited. Hypertension Canada does not provide medical advice, diagnosis or treatment. (...) Treatment of Secondary Hypertension Due to Endocrine Causes XIV. Treatment of Secondary Hypertension Due to Endocrine Causes | Hypertension Canada Guidelines Subgroup Members: Ally P.H. Prebtani, MD; Gregory Kline, MD, Ernesto L. Schiffrin, MD PhD; Andrew Don-Wauchope, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH

2018 Hypertension Canada

274. Diagnosis & Assessment of Hypertension - Endocrine Hypertension

; Patients with a predisposition to hereditary causes (e.g., multiple endocrine neoplasia 2A or 2B, von Recklinghausen neurofibromatosis type 1, Von Hippel-Lindau disease); For patients with positive biochemical screening tests, localization of pheochromocytomas or paragangliomas should employ magnetic resonance imaging (preferable), computed tomography (if magnetic resonance imaging is unavailable), and/or iodine I-131 metaiodobenzylguanidine (MIBG) scintigraphy (Grade C for each modality). Background (...) in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999;340:1872-9. Sawka AM, Prebtani AP, Thabane L, Gafni A, Levine M, Young WF Jr. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord 2004;4:2. Lenders et al Guidelines on Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab 2014;99:1915–1942. Sjoberg RJ, Simcic KJ

2018 Hypertension Canada

275. Cabometyx (cabozantinib) - advanced renal cell carcinoma

QT interval by Fridericia R responder RBC red blood cell RCC renal cell carcinoma RECIST Response Evaluation Criteria In Solid Tumors SAE serious adverse event SAP Statistical Analysis Plan SBP systolic blood pressure SD stable disease SOC system organ class SoD sum of lesion diameters SoD sum of lesion diameters SRE skeletal-related event TBS technetium bone scans TEAE treatment-emergent adverse event TIA transient ischemic attack TORC1 target of rapamycin complex 1 TSH thyroid-stimulating (...) carcinoma (RCC) in patients who have received one prior therapy. The approved indication further to the CHMP review is: CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy 2.1.1. Disease or condition Renal cell carcinomas are kidney tumours which represent approximately 90% of cases of kidney cancer in adults (Wahal and Mardi, 2014). These tumours arise from the cells of the proximal renal

2016 European Medicines Agency - EPARs

276. Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Endocrine Gland Neoplasms Pancreatic Diseases Endocrine System Diseases Bevacizumab Durvalumab Capecitabine Antibodies, Monoclonal Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors (...) Colorectal Adenocarcinoma Pancreatic Adenocarcinoma Metastatic Pancreatic Cancer Drug: Durvalumab Biological: CV301 Drug: Capecitabine Drug: Bevacizumab Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 54 participants Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus

2017 Clinical Trials

277. Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Pancreas vaccine immunotherapy antibody PD-1 IMC-CS4 Pembrolizumab GVAX Borderline Resectable Additional relevant MeSH terms: Layout table for MeSH terms Adenocarcinoma Pancreatic Neoplasms Carcinoma Neoplasms, Glandular and Epithelial (...) Neoplasms by Histologic Type Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Vaccines Cyclophosphamide Pembrolizumab Pancrelipase Pancreatin Immunologic Factors Physiological Effects of Drugs Immunosuppressive Agents Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antineoplastic Agents

2017 Clinical Trials

278. A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Product: No Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Immunotherapy Nivolumab Entinostat Pancreatic Adenocarcinoma Cholangiocarcinoma Unresectable Metastatic PD-1 Antibody Additional relevant MeSH terms: Layout table for MeSH terms Adenocarcinoma Pancreatic Neoplasms Cholangiocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System (...) and procedures. Are pregnant or breastfeeding. Infection with HIV or hepatitis B or C. Patients on immunosuppressive agents. Requiring concurrent administration of valproic acid. Patients with diverticulitis, intra-abdominal abscess, or GI obstruction Any contraindication to oral agents. Another active malignancy ≤ 3 years prior to registration with the exception of non-melanotic skin cancer or carcinoma-in-situ of any type. Unwilling or unable to follow the study schedule for any reason. Evidence of ascites

2017 Clinical Trials

279. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms Full Text available with Trip Pro

parameters to identify PCC patients at risk of disseminated disease. Since the algorithms are derived from studies using predominantly sporadic PCCs, little is known whether the PASS or GAPP scores can predict malignant potential in hereditary cases.PASS and GAPP were applied on 41 PCCs; 13 PCCs were diagnosed in ten multiple endocrine neoplasia type 2A (MEN 2A) patients carrying established germline RET proto-oncogene mutations, as well as 28 assumed sporadic PCCs.Six out of thirteen MEN 2A tumors (46 (...) %) exhibited PASS scores ≥ 4, indicative of a potential for aggressive behavior. In addition, 7/13 tumors (54%) exhibited GAPP scores ≥ 3, indicative of a "moderately differentiated type" with risk of future recurrence. All MEN 2A PCCs with an elevated PASS score also displayed an elevated GAPP score. In contrast, 4/28 (14%) sporadic PCCs demonstrated PASS scores ≥ 4, and 9/28 (32%) displayed GAPP scores ≥ 3. Follow-up found all cases in the study are free of metastatic or recurrent disease.We conclude

2018 Langenbeck's Archives of Surgery

280. A Study of RGX-202-01 With or Without FOLFIRI in Patients With Advanced Gastrointestinal Malignancies

/gastroesophageal cancer and CRC). Condition or disease Intervention/treatment Phase Gastrointestinal Cancer Gastrointestinal Neoplasms Colorectal Cancer Colorectal Neoplasms Colorectal Carcinoma Gastric Cancer Gastric Neoplasm Pancreatic Cancer Pancreatic Neoplasm Drug: RGX-202-01 Drug: FOLFIRI Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 60 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment (...) /metastatic disease. Patients treated with more than one prior regimen must be approved by the Medical Monitor. Only patients exhibiting positive expression of SLC6a8 in tumor cells detected by an immunohistochemistry (IHC) method will be enrolled. For the combination therapy expansion cohort, patients with gastroesophageal junction or gastric cancer must have received only one prior systemic regimen in the metastatic setting. Prior therapy with a checkpoint inhibitor (PD-1/PD-L1 inhibitor) is allowed

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>